Portal de Periódicos da CAPES

ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE

2000; Lippincott Williams & Wilkins; Volume: 164; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)67455-1

1527-3792

Misop Han, Patrick C. Walsh, Alan W. Partin, Ronald Rodríguez,

Prostate Cancer Treatment and Research

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jul 2000ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE MISOP HAN, PATRICK C. WALSH, ALAN W. PARTIN, and RONALD RODRIGUEZ MISOP HANMISOP HAN , PATRICK C. WALSHPATRICK C. WALSH , ALAN W. PARTINALAN W. PARTIN , and RONALD RODRIGUEZRONALD RODRIGUEZ View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67455-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In a revised 1997 edition the American Joint Committee on Cancer (AJCC) staging for prostate cancer reduced the subdivision of T2 disease from 3 (T2a, T2b and T2c) to 2 substages by combining single lobe disease (T2a and T2b) into a single stage, now termed T2a. We retrospectively reviewed a large series of men with clinically organ confined prostate cancer who underwent surgery by a single surgeon to determine how this change affected the ability of the staging system to predict outcome. Materials and Methods: Of 2,293 cases treated with radical prostatectomy from 1982 to 1998, 1,314 were clinically staged to have T2 disease. We analyzed the freedom from biochemical prostate specific antigen (PSA) progression after radical prostatectomy according to the 1992 and 1997 AJCC staging criteria. Results: Overall the actuarial 5 and 10-year biochemical progression-free survival rates for the whole group were 82% and 71%, respectively. The actuarial recurrence-free rate was significantly different for patients with 1992 AJCC T2a (T2a92) versus T2b (T2b92) disease (p <0.0001) but similar for those with 1992 T2b versus T2c (T2c92) disease (p = 0.1165). The actuarial recurrence-free rate was significantly different for patients with 1997 AJCC T2a (T2a97) versus T2b (T2b97) disease (p = 0.0001). However, the overall recurrence-free rate was lower in the T2a97 group compared with the T2a92 group. Conclusions: The 1992 AJCC staging of T2 prostate cancer yielded a significant difference in the outcome of patients with single lobe disease (T2a92 and T2b92), which is obscured by the 1997 staging criteria. Therefore, we believe that the next revision of the AJCC staging system should revert back to the 1992 AJCC system of subdividing a single lobe disease category into T2a and T2b. Alternatively the committee may want to merge T2b92 and T2c92 stages into a new staging entity, since there was no statistical difference in the outcome of these 2 groups. References 1 : The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am1975; 2: 105. Google Scholar 2 : Hormone therapy in prostate cancer. Am J Med1956; 21: 697. Google Scholar 3 : . Philadelphia: Lippincott1992: 181. Google Scholar 4 : 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol1994; 152: 1837. Link, Google Scholar 5 : Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol1998; 160: 2428. Link, Google Scholar 6 : Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am1997; 24: 395. Google Scholar 7 : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol1994; 152: 1850. Link, Google Scholar 8 : . Philadelphia: Lippincott1997: 219. Google Scholar 9 : Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy. Cancer1999; 85: 1816. Google Scholar 10 Iyer, R. V.: Personal communication Google Scholar 11 : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA1997; 277: 1445. Google Scholar 12 : Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol1994; 152: 1843. Link, Google Scholar 13 : The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol1994; 152: 1821. Link, Google Scholar From the Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKordan Y, Chang S, Salem S, Cookson M, Clark P, Davis R, Herrell S, Baumgartner R, Phillips S, Smith J and Barocas D (2018) Pathological Stage T2 Subgroups to Predict Biochemical Recurrence After ProstatectomyJournal of Urology, VOL. 182, NO. 5, (2291-2295), Online publication date: 1-Nov-2009. (2018) Re: Improved Clinical Staging System Combining Biopsy Laterality and TNM Stage for Men With T1c and T2 Prostate Cancer: Results From the Search Database: Reply by Authors.Journal of Urology, VOL. 171, NO. 3, (1246-1247), Online publication date: 1-Mar-2004.FREEDLAND S, PRESTI J, TERRIS M, KANE C, ARONSON W, DOREY F and AMLING C (2018) Improved Clinical Staging System Combining Biopsy Laterality and TNM Stage for Men With T1c and T2 Prostate Cancer: Results From the SEARCH DatabaseJournal of Urology, VOL. 169, NO. 6, (2129-2135), Online publication date: 1-Jun-2003.GROSSKLAUS D, COFFEY C, SHAPPELL S, JACK G, CHANG S and COOKSON M (2018) Percent Of Cancer in the Biopsy Set Predicts Pathological Findings After ProstatectomyJournal of Urology, VOL. 167, NO. 5, (2032-2036), Online publication date: 1-May-2002.D’AMICO A, WHITTINGTON R, MALKOWICZ S, WEINSTEIN M, TOMASZEWSKI J, SCHULTZ D, RHUDE M, ROCHA S, WEIN A and RICHIE J (2018) PREDICTING PROSTATE SPECIFIC ANTIGEN OUTCOME PREOPERATIVELY IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, VOL. 166, NO. 6, (2185-2188), Online publication date: 1-Dec-2001.HAN M, POUND C, POTTER S, PARTIN A, EPSTEIN J and WALSH P (2018) ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONSJournal of Urology, VOL. 165, NO. 3, (864-866), Online publication date: 1-Mar-2001. Volume 164Issue 1July 2000Page: 89-92 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsrecurrenceneoplasm stagingprostateprostatectomyprostatic neoplasmsMetricsAuthor Information MISOP HAN More articles by this author PATRICK C. WALSH More articles by this author ALAN W. PARTIN More articles by this author RONALD RODRIGUEZ More articles by this author Expand All Advertisement PDF downloadLoading ...